Chinese Sinovac Testing COVID-19 Vaccine in Brazil
In the race to develop the world’s first COVID-19 vaccine, Brazil – now one of the world’s worst-affected countries – is becoming an attractive clinical trial destination for biopharma companies…
Address: 22F, N.138 Pudong Avenue
Shanghai 200120 P.R. China ,China
Tel: +86 21 5888 2200
Web: http://www.boehringer-ingelheim.com.cn/
Entering the Chinese market in 1994, Boehringer Ingelheim investment ushered in vigorous development. Boehringer Ingelheim has excellent products in the prescription drugs, consumer self-care medicines and animal health field in the Chinese market and are widely recognized by consumers.
Since 2002, the company has been based in Shanghai. The Zhangjiang Hi-Tech Park factory was built to demonstrate the Boehringer Ingelheim’s determination to further establish itself in China. The Zhangjiang plant has introduced the world’s most advanced pharmaceutical equipment, design and management standards to the country and is comparable to Boehringer Ingelheim plants in any part of the world. The factory operates in strict accordance to international GMP standards. Boehringer Ingelheim’s investment in China amounts $ 29,000,000. The Company has offices in Shanghai, in Beijing, Guangzhou, Shenyang, Chengdu, Nanjing, Hangzhou and has also set up branches in other places, employing a total of more than 2,000 people.
Boehringer Ingelheim’s main business in China includes prescription drugs, consumer self-care medicines and animal health. The business scope encompasses all of the country’s major cities and regions. The company will continue to pursue new drug and disease treatment programs and Boehringer Ingelheim products have gained an excellent reputation in the market, benefitting millions of patients.
Looking ahead, Boehringer Ingelheim Shanghai looks forward to even greater success in the Chinese market, including in the field of human medicine, the company wants to be the key leader in the respiratory, cardiovascular, central nervous system, diabetes and cancer fields. as well as animal health.
With a solid foundation built up over more than a century, Boehringer Ingelheim strives to make greater contributions to Chinese medical and health undertakings.
respiratory, cardiovascular, central nervous system, diabetes, oncology
In the race to develop the world’s first COVID-19 vaccine, Brazil – now one of the world’s worst-affected countries – is becoming an attractive clinical trial destination for biopharma companies…
The latest news from Chinese pharma, including the latest on Sinopharm’s COVID-19 vaccine, how geopolitical tensions are affecting trade between China and India, and the country’s latest pharma billionaire. …
I recently had the pleasure to moderate an event on the COVID-19 impact on the relationship between Doctor and Patient, attended by 50 executives of the French Healthcare community in…
Chinese biotech CanSinoBIO is racing against the clock to have a COVID-19 vaccine ready to begin production in early 2021. The firm’s senior VP of International Business Pierre Morgon reflects…
Founded by a veteran industry team, Arctic Vision recently celebrated its first anniversary and touts itself as the first innovative ophthalmology-focused biotech in China, with the mission of bringing innovative…
Dr Eddy Wu, founder and CEO of new Chinese ophthalmology biotech Arctic Vision outlines the specific unmet ophthalmology needs in the Chinese market, the company’s burgeoning international partnerships, exciting portfolio,…
Yan Tan, CEO of Xbiome, the first AI-based microbiome drug development company in China, outlines the rationale behind the firm’s founding, what makes its technology platform unique, and the challenges…
2020 will certainly go down in history as a watershed year for the global community, as a new strain of coronavirus – later named SARS-CoV-19 – originating from the city…
A roundup of the latest news from Chinese biotechs, including a bumper IPO for Legend Biotech, a USD two million tie-up between Roche and Innovent Biologics, and a new Alphamab-Sanofi…
Johnson & Johnson’s network of healthcare innovation incubators, JLABS, opened its doors in Shanghai in June 2019 and now stands as the largest such institution of 13 globally. JLABS @…
Pierre A Morgon, SVP International Business for CanSino Biotechnology (CanSinoBIO) – a Chinese vaccine biotech developing one of the frontrunner COVID-19 vaccine candidates – shares how his extensive international career…
Highly potent neutralizing antibodies may be the key to laying a foundation for COVID-19 treatment, according to a Chinese research team led by Peking University. The worldwide race against…
See our Cookie Privacy Policy Here
